Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib Plus Erlotinib vs. Sorafenib Plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)

NCT00901901 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00901901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00901901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib Plus Erlotinib vs. Sorafenib Plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
May 21, 2009
Completion date
May 23, 2018
Enrollment
732 (actual)
Sites
127

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular